The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Abstract
OBJECTIVE: Eszopiclone is a new, single-isomer, non-benzodiazepine, cyclopyrrolone agent under investigation for the treatment of insomnia. The present study was a randomized, double-blind, multicenter, placebo-controlled trial conducted to assess the efficacy and safety of eszopiclone in adults with chronic primary insomnia. RESEARCH DESIGN AND METHODS: Patients (n = 308) were randomized to receive placebo or eszopiclone (2 mg or 3 mg) for 44 consecutive nights, followed by 2 nights of single-blind placebo. Efficacy was evaluated with polysomnography (Nights 1, 15 and 29) and patient-reports (Nights 1, 15, 29 and 43/44). Next-day residual effects were evaluated using the Digit-Symbol Substitution Test (DSST). RESULTS: Eszopiclone 3 mg had significantly less time to sleep onset (p < or = 0.0001), more total sleep time and sleep efficiency (p < or = 0.0001), better sleep maintenance (p < or = 0.01), and enhanced quality and depth of sleep (p < 0.05) across the double-blind period compared with placebo. Eszopiclone 2 mg had significantly less time to sleep onset (p < or = 0.001), more total sleep time (p < or = 0.01) and sleep efficiency (p < or = 0.001), and enhanced quality and depth of sleep (p < 0.05) compared with placebo, but did not significantly improve sleep maintenance. There was no evidence of tolerance or rebound insomnia after therapy discontinuation. Median DSST scores showed no decrement in psychomotor performance relative to baseline and did not differ from placebo in either eszopiclone group. Treatment was well tolerated; the most common adverse event related to eszopiclone was unpleasant taste. CONCLUSIONS: Patients treated with nightly eszopiclone 3 mg had better polysomnographic (through Night 29) and patient-reported measures (through Night 44) of sleep over the 6-week trial. There was no evidence of tolerance or rebound insomnia and no detrimental effects on next-day psychomotor performance using the DSST.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of insomnia: what we know and what we still need to learn
Ohayon, M. M. (2002) · Sleep Medicine Reviews · doi:10.1053/smrv.2002.0186 · Cited by 3,743
Insomnia and Its Treatment: Prevalence and Correlates
Mellinger, G. D. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790260019002 · Cited by 1,071
Ancoli‐Israel, S., & Roth, T. G. (1999) · PubMed · Cited by 776
Self-citationKrystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
Self-citationDaytime Alertness in Patients with Chronic Insomnia Compared with Asymptomatic Control Subjects
Stepanski, E., Zorick, F., Roehrs, T., Young, D., & Roth, T. (1988) · Sleep · doi:10.1093/sleep/11.1.54 · Cited by 302
Self-citationInsomnia and its treatment: When are hypnotics justified?
Malcolm, R., & Gross, J. A. (1984) · Postgraduate Medicine · doi:10.1080/00325481.1984.11698665 · Cited by 290
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf, M. B., Roth, T. G., Vogel, G. W., & Walsh, J. K. (1994) · PubMed · Cited by 223
Self-citationElie, R., Ruther, E., Farr, I., Emilien, G., Salinas, E., & The Zaleplon Clinical Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0806 · Cited by 191
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188
Reported chronic insomnia is independent of poor sleep as measured by electroencephalography
Rosa, R. R., & Bonnet, M. H. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200007000-00004 · Cited by 174
Cited by
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Recommendations for a standard research assessment of insomnia
Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Lichstein, K. L., & Morin, C. M. (2006) · Sleep · doi:10.1093/sleep/29.9.1155 · Cited by 1,206
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Metadata
- Authors
- Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2004-11-24
- Volume
- 20
- Issue
- 12
- Pages
- 1979-1991
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1977894152
- Cited by
- 294
- References
- 40
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. https://app.cochat.ai/papers/10.1185/174234304x15174
- The paper
- Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004). Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Current Medical Research and Opinion. https://doi.org/10.1185/174234304x15174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.